COVID-19 — Vaccine Injury Compensation: Legal and Policy Landscape
COVID-19 — Vaccine Injury Compensation: Legal and Policy Landscape
[edit | edit source]Overview
[edit | edit source]The legal and policy landscape for COVID-19 vaccine injury compensation is one of the most contested and least transparent areas of the pandemic response. Vaccine manufacturers received broad liability protection in the United States and elsewhere through specific legislation. Government compensation programs were established but have faced significant criticism for insufficient funding, limited scope, high evidentiary bars, and lengthy processing backlogs.
Manufacturer Liability Protection
[edit | edit source]United States: PREP Act
[edit | edit source]In the United States, COVID-19 vaccine manufacturers received immunity from liability*** under the Public Readiness and Emergency Preparedness (PREP) Act***, which had been in effect for pandemic countermeasures since 2005. Under the PREP Act:
- Vaccine manufacturers cannot be sued for vaccine injuries through the normal civil court system
- Claims must be directed to the government's compensation program
- Liability is only restored in cases of "willful misconduct"
This liability protection was among the most criticized aspects of the U.S. vaccine rollout from injured persons' advocates: individuals who suffered documented, confirmed vaccine injuries — including TTS from AstraZeneca and myocarditis from mRNA vaccines — found their ability to sue manufacturers in civil court was eliminated.
The CICP: The U.S. Compensation Program
[edit | edit source]The Countermeasures Injury Compensation Program (CICP)*** is the U.S. government program established under the PREP Act to compensate individuals seriously injured by pandemic countermeasures including COVID-19 vaccines.
| Feature | CICP | VICP (for comparison) |
|---|---|---|
| Program type | Administrative claim to HHS | No-fault compensation; U.S. Court of Federal Claims |
| Applicable vaccines | Pandemic countermeasures (COVID-19) | Routine vaccines (flu, MMR, etc.) |
| Standard of proof | Claimant must prove causation | More plaintiff-favorable; vaccine injury table |
| Compensation for pain and suffering | No | Yes |
| Compensation cap | Yes | Higher cap |
| Legal representation | Not provided; claimant bears cost | Legal fees may be reimbursed |
| COVID-19 claim acceptance rate (through 2024) | Very low; approximately 1–3% accepted | Higher historically |
Critics note that the CICP was widely considered inadequate before COVID-19 and remained so through the pandemic. By 2024, the program had received tens of thousands of COVID-19 vaccine injury claims but had compensated a very small fraction of them.
The UK Vaccine Damage Payment Scheme
[edit | edit source]The United Kingdom's Vaccine Damage Payment Scheme (VDPS)*** provides a one-time payment (currently £120,000) to individuals who suffer at least 60% disability as a result of a vaccine. The scheme received thousands of COVID-19 claims that created a significant backlog. As of 2024, many claims remained unresolved years after submission — a situation that the UK's Parliamentary and Health Service Ombudsman criticized as unacceptable.
The UK situation is particularly significant because the AstraZeneca vaccine TTS liability cases — pursued through civil courts when claimants argued the government's compensation was insufficient — produced the corporate acknowledgment of TTS causation described in the adverse events article.
The International Compensation Landscape
[edit | edit source]Compensation approaches varied significantly internationally:
- New Zealand***: Established a COVID-19 Vaccine Injury Compensation Programme with broader coverage than many other countries
- Germany***: Established compensation; acknowledged TTS as compensable
- Japan***: Created a compensation scheme; processed claims
- Australia***: The COVID-19 Vaccine Claims Scheme provided compensation for specified serious adverse events
The variation in national compensation schemes reflects differing national judgments about the appropriate scope of government responsibility for injuries from government-mandated or government-encouraged health interventions.
